C.F.R. homeSearch C.F.R.
C.F.R.Title 42Chapter IV—Centers for Medicare & Medicaid Services, Department of Health and Human ServicesSubchapter B—Medicare ProgramPart 405—Federal Health Insurance for the Aged and DisabledSubpart E—Criteria for Determining Reasonable Charges

42 C.F.R. § 405.517 (2026)

Payment for drugs and biologicals that are not paid on a cost or prospective payment basis

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1998–2015 20citing cases
At a glance

Courts have cited this section in 20 opinions since 1998. The most litigated part is subsection (b) (1 case).

(a) Applicability—(1) Payment for drugs and biologicals before January 1, 2004. Payment for a drug or biological that is not paid on a cost or prospective payment basis is determined by the standard methodology described in paragraph (b) of this section. Examples of when this procedure applies include a drug or biological furnished incident to a physician's service, a drug or biological furnished by an independent dialysis facility that is not included in the ESRD composite rate set forth in § 413.170(c) of this chapter, and a drug or biological furnished as part of the durable medical equipment benefit.

(2) Payment for drugs and biologicals on or after January 1, 2004. Effective January 1, 2004, payment for drugs and biologicals that are not paid on a cost or prospective payment basis are paid in accordance with part 414, subpart I of this chapter.

(3) Payment for drugs and biologicals on or after January 1, 2005. Effective January 1, 2005, payment for drugs and biologicals that are not paid on a cost or prospective payment basis are paid in accordance with part 414, subpart K of this chapter.

(b) Methodology. Payment for a drug or biological described in paragraph (a) of this section is based on the lower of the actual charge on the Medicare claim for benefits or 95 percent of the national average wholesale price of the drug or biological.

(c) Multiple-source drugs. For multiple-source drugs and biologicals, for purposes of this regulation, the average wholesale price is defined as the lesser of the median average wholesale price for all sources of the generic forms of the drug or biological or the lowest average wholesale price of the brand name forms of the drug or biological.

[63 FR 58905, Nov. 2, 1998, as amended at 69 FR 1116, Jan. 7, 2004; 69 FR 66420, Nov. 15, 2004]
The 20 cases that cite 42 C.F.R. § 405.517 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 230 F.R.D. 61 (D. Mass. 2005).
cites § 405.517 5×cited by 71 cases
Where it cites § 405.517
“§§ 1395u(o), 13951(s); 42 C.F.R. § 405.517 . From 1992 to 1997, reimbursement for single-source brand-name drugs was set at the lesser of the estimated acquisition cost (“EAC”) or AWP.”
The case’s holding
Manageability is a key factor in a superiority determination under Rule 23, focusing on pragmatic concerns regarding the efficient adjudication of the controversy.
Later courts cite it for
“a key factor in making this superiority determination is manageability, which focuses on pragmatic concerns.” · 3 citing courts
2
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 491 F. Supp. 2d 20 (D. Mass. 2007).
cites § 405.517 3×cited by 57 cases
Where it cites § 405.517
“See 42 C.F.R. § 405.517 (1999) (Department of Health and Human Services (“DHHS”) Regulations); see also 42 U.”
The case’s holding
Publishing inflated average wholesale prices to create spreads exceeding industry expectations constitutes unfair and deceptive trade practices under Massachusetts law.
Later courts cite it for
“from the markup charged by wholesalers over their actual acquisition cost.” · 7 citing courts
3
GREENIn re Pharm. Indus. Average Wholesale Price Lit., 582 F.3d 156 (1st Cir. 2009).
cites § 405.517 2×cited by 88 cases
Where it cites § 405.517
“at 59,621 (promulgating 42 C.F.R. § 405.517 (1992)) (emphasis added).”
The case’s holding
Federal Medicare statutes do not preempt state consumer protection laws from addressing pharmaceutical companies that engage in unfair and deceptive practices by inflating average wholesale prices.
Later courts cite it for
“the crucial factors in an unfairness inquiry are the nature of the challenged conduct and on the purpose and effect of that conduct.” · 2 citing courts
4
GREENIn re Lupron® Mktg. & Sales Practices Litig., 295 F. Supp. 2d 148 (D. Mass. 2003).
cites § 405.517 2×cited by 70 cases
Where it cites § 405.517
“42 C.F.R. § 405.517 . 7 Medicare administrators historically relied on the AWP in setting the reimbursement rate for Lupron®.”
The case’s holding
Federal preemption does not bar RICO or state consumer protection claims based on affirmative misrepresentations of drug prices to insurers.
Later courts cite it for
“a successful civil rico action requires proof of four elements: (1) conduct (2) of an enterprise (3) through a pattern (4) of racketeering activity.” · 2 citing courts
5
GREENIn re Lupron Mktg. & Sales Practices Litig., 228 F.R.D. 75 (D. Mass. 2005).
cites § 405.517 2×cited by 39 cases
Where it cites § 405.517
“42 C.F.R. § 405.517 (amended Nov. 2, 1998; Jan.”
The case’s holding
A class action settlement is fair and reasonable if it provides a substantial benefit to the class despite limited discovery or an expedited timeline.
Later courts cite it for
“the storm warnings indicative of collusion are a 'lack of significant discovery and an extremely expedited settlement of questionable value accompanied by an enormous legal fee.” · 4 citing courts
cites § 405.517 6×cited by 5 cases
Where it cites § 405.517
“§ 1395u(o); 42 C.F.R. § 405.517 (1998) (amended 1998, 2004); 42 C.”
7
GREENIn re Lupron Mktg. & Sales Practices Litig., 245 F. Supp. 2d 280 (D. Mass. 2003).
cites § 405.517 2×cited by 28 cases
Where it cites § 405.517
“6 42 C.F.R. § 405.517 . Medicare administrators historically relied on the AWP provided by TAP to the Red Book, an industry compilation of wholesale drug prices, in setting the reimbursement rate for Lupron®.”
Later courts cite it for
“a parent's oversight of a subsidiary's business plans is not ordinarily a sufficient 'plus' to tip the jurisdictional scale,” · 2 citing courts
8
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 460 F. Supp. 2d 277 (D. Mass. 2006).
cites § 405.517 2×cited by 23 cases
Where it cites § 405.517
“at 59,621 (promulgating 42 C.F.R. § 405.517 (1992)) (emphasis added).”
The case’s holding
Under the Medicare statute, average wholesale price is construed by its plain meaning as an average of actual wholesale prices, not an industry-published sticker price.
Later courts cite it for
“far more than the 'average' price that we believe the law intended them to pay,” · 2 citing courts
cites § 405.517 3×subsections: (b)cited by 19 cases
Where it cites § 405.517
“§§ 1395k, 1395Z, 1395u(o)(l); 42 C.F.R. § 405.517 (b) (1998). In October 1996, Palmetto Government Benefits Administrators (Palmetto), which administers Medicare Part B benefits in South Carolina under the authority of the Health Care Financing Administration and the United…”
Later courts cite it for
“when congress passes a statute regulating a defined class, its intention to limit the class must be given the same respect as its intention to regulate it.” · 2 citing courts
10
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 263 F. Supp. 2d 172 (D. Mass. 2003).
cites § 405.517 1×cited by 51 cases
The case’s holding
State consumer protection claims are not preempted by the Medicare Act without clear congressional intent to displace state power in traditionally regulated fields like medical fee regulation.
Later courts cite it for
“the guiding principle throughout the preemption analysis is congressional intent.” · 2 citing courts
11
GREENCommonwealth ex rel. Pappert v. TAP Pharm. Prods., Inc., 885 A.2d 1127 (Pa. Commw. Ct. 2005).
cites § 405.517 1×cited by 45 cases
Where it cites § 405.517
“42 C.F.R. § 405.517 . Medicare pays 80% of the allowable amount, i.”
The case’s holding
A party alleging unjust enrichment must establish that the plaintiff conferred a benefit, the defendant appreciated the benefit, and retention of the benefit without payment is inequitable.
Later courts cite it for
“additionally, the plaintiff bears the burden of establishing either that the defendant wrongfully secured the benefit or passively received a benefit that it would be unconscionable to retain.” · 3 citing courts
12
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 252 F.R.D. 83 (D. Mass. 2008).
cites § 405.517 1×cited by 36 cases
Where it cites § 405.517
“Effective January 1, 1998, pursuant to a statutory change, the Medicare regulations were amended to provide reimbursement for the lower of the billed charge or 95 percent of AWP.”
The case’s holding
A class spanning many states' unfair trade practice statutes is rarely certifiable but not barred, and plaintiffs must show how state-law variances can be grouped or overcome for predominance and manageability.
Later courts cite it for
“most manufacturers continued to report awps consistent with the historic 20 to 25 percent markup, even though they knew that wholesalers were not actually charging these prices to providers and thus that the awp relied on by medicare and the third-party payors was not a true average price charged by wholesalers.” · 7 citing courts
13
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 307 F. Supp. 2d 196 (D. Mass. 2004).
cites § 405.517 1×cited by 27 cases
Where it cites § 405.517
“” 42 C.F.R. § 405.517 (2003). No one drug maker could gain an advantage by leapfrogging the AWP over a competitor’s, Defendants argue, as reimbursement is based on the median.”
14
GREENMontana v. Abbot Labs., 266 F. Supp. 2d 250 (D. Mass. 2003).
cites § 405.517 1×cited by 27 cases
The case’s holding
Where a state-law claim requires violation of a federal statute, federal-question jurisdiction exists only if that statute provides a private remedy; removal requires all served defendants to join or assent.
Later courts cite it for
“all defendants who have been served must join or assent in the removal petition.” · 4 citing courts
15
GREENIn re Pharm. Ind. Average Wholesale Price Lit., 491 F. Supp. 2d 12 (D. Mass. 2007).
cites § 405.517 1×cited by 15 cases
Later courts cite it for
“medicare program requires providers to affirmatively certify that they have complied with the anti-kickback statute; failure to comply with the kickback laws, therefore, is, in and of itself, a false statement to the government” · 4 citing courts
16
GREENIn re Pharm. Indus. Average Wholesale Price Litig., 457 F. Supp. 2d 77 (D. Mass. 2006).
cites § 405.517 1×cited by 7 cases
Where it cites § 405.517
“§ 1395u(o); 42 C.F.R. § 405.517 (b) (2006). In 2004, reimbursement under the statute was reduced to 85 percent of AWP.”
17
GREENBlue Cross Blue Shield v. AstraZeneca Pharm. LP, 582 F.3d 156 (1st Cir. 2009).
cites § 405.517 2×cited by 10 cases
Where it cites § 405.517
“at 59,621 (promulgating 42 C.F.R. § 405.517 (1992)) (emphasis added).”
cites § 405.517 1×cited by 4 cases
Summary
No passage or summary on file for this case yet.
19
NEUTRALUnited States ex rel. Saldivar v. Fresenius Med. Care Holdings, Inc., 145 F. Supp. 3d 1220 (N.D. Ga. 2015).
cites § 405.517 2×cited by 1 case
Where it cites § 405.517
“4 See 42 C.F.R. § 405.517 ; Medicare Payment Advisory Commission (“Med-PAC”), Report to the Congress: Medicare Payment Policy, § 2F: Outpatient dialysis services, at 104-105 (March 2002) (hereinafter “2002 MedPAC Report).”
20
NO FLAGTAP Pharm. v. HHS, No. 97-2773 (4th Cir. Nov. 30, 1998).
cites § 405.517 3×cited by 0 cases
Where it cites § 405.517
“§§ 1395k, 1395l, 1395u(o)(1); 42 C.F.R. § 405.517 (b) (1998). In October 1996, Palmetto Government Benefits Administrators (Palmetto), which administers Medicare Part B benefits in South Car- olina under the authority of the Health Care Financing Administration and the United…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199820062015

One bar per year. Tallest: 4 cases in 2003. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D. Mass.141st Cir.24th Cir.2N.D. Ga.1Pa. Commw. Ct.1
By subsection
(b)1 case
Tap Pharm. v. U.S. Dep't of Health & Human Servs. Health Care Fin. Admin. Palmetto Gov't Benefits Administrators, 163 F.3d 199 (4th Cir. 1998).“§§ 1395k, 1395Z, 1395u(o)(l); 42 C.F.R. § 405.517 (b) (1998). In October 1996, Palmetto Government Benefits Administrators (Palmetto), which administers Medicare Part B benefits in South Carolina under the authority of the Health Care Financing Administration and the United…”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com